Speaker: Evandro de Azambuja

0:02:58

APHINITY: OS in HER2-positive breast cancer

0:12:16

De-escalation and escalation strategies for HER2+ breast cancer

0:01:14

Prognostic value of beta-2 adrenergic receptor levels in HER2+ breast cancer

0:02:27

MONARCH: Chemo-free options for triple-positive metastatic breast cancer

0:02:06

NGS multi-panel gene testing for newly diagnosed patients with metastatic breast cancer

0:03:57

Nationwide study by the BCR and BSMO on the effect of surgery on mBC patients

0:02:58

OlympiA: adjuvant olaparib following chemo significantly improves IDFS

0:03:26

Chemo-immunotherapy for TNBC

0:02:01

Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer

0:02:13

Effects of BMI on PFS in the MONARCH 1 and MONARCH 2 trial

0:02:06

PHranceSCa: evaluating patient satisfaction with subcutaneous pertuzumab and trastuzumab treatment

0:07:32

Cardiac safety in the APHINITY study

0:01:30

Results of the Phase II GeparNuevo trial

0:06:09

Adjuvant endocrine therapy for breast cancer: optimal durations and regimens

0:02:29

Early response and long-term outcomes in the CLEOPATRA trial

0:31:44

How can international collaboration benefit young researchers?

0:02:24

Improving fertility and pregnancy issues in young breast cancer patients

0:02:37

Anti-HER2 strategies in breast cancer: the ALTTO trial

0:49:42

IACH Journal Club: Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in 1st Remission

0:06:45

Innovative biomarker approaches in breast cancer therapy

0:03:58

Demonstração da análise sonora Lanceiros Negros

0:08:18

Prof. Nicholas Pavlidis-Prof. of Medical Oncology Medical School, University of Ioannina

3:48:41

Breast Cancer: OncoAlert Colloquium Year in Review

0:03:50

Breast cancer at ESMO 2020: IMpassion131, SOLAR-1, PALLAS and more